NASDAQ · Services · Services-home health care services
$31.61−$0.1000 (−0.32%) on the dayAs of the close; data may be delayed.
OPCH price, last 12 months
$36.59$19.52$31.61
Daily closes over the last 260 trading sessions: +14.3%. Highest close $36.59 on , lowest $19.52 on . Market data may be delayed.
Key stats
Previous close
$31.71
Open
$31.71
Day range
$31.58 – $31.72
52-week range
$18.01 – $36.80
Volume
2.7M
Avg volume (20 days)
3.6M
Market cap
$4.7B
Performance
1W−0.2%
1M+1.0%
3M+33.5%
6M+50.9%
YTD−0.9%
1Y+13.8%
vs S&P 500, 1Y+9.7 pts
Technicals and fundamentals
About Option Care Health, Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
Chart OPCH with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full OPCH chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Daily range (ATR)0.7%average true range, % of price
52w low $18.0152w high $36.80
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)22.00.88x Services median (24.9)
P/E (forward)15.2
PEG1.50
Price / sales0.82
Price / book3.57
EV / EBITDA—
P/E since Jun 114.4 – 22.7
Company figures as of Nov 20, 2026.
Analysts
ConsensusHold3.0 on 1 (strong buy) to 5 (strong sell)
Analysts8
Average target$30.03−4.9% from today
Price targets are opinions and tend to lean optimistic.
Earnings
Next results, expectedaround Jan 11, 2027 (in 51 days)A year after its Jan 12, 2026 results release; the last came Nov 4, 2026. An estimate from its SEC filings, not a date the company announced.
Dividends & splits
No dividends on record.
Splits
Feb 3, 20201-for-4 (reverse)
Seasonality
+2.2
J
+4.7
F
+1.2
M
-7.4
A
-1.8
M
+0.4
J
+6.5
J
+0.5
A
-3.0
S
+0.6
O
+4.4
N
+5.1
D
Average return in each calendar month, Oct 31, 2021 to Oct 31, 2026. 6 years is 6 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
+7
−5
−17
−24
+3
+0
+10
+2
−4
+42
0%
2025
+33
+8
+4
−8
+1
−1
−10
−2
−3
−6
+19
+2
+37%
2024
−7
+3
+4
−11
−0
−7
+7
+8
−2
−26
+3
−3
−31%
2023
−4
+6
+4
+1
−14
+18
+4
+3
−7
−14
+7
+13
+12%
2022
−18
+10
+11
+5
+2
−8
+21
−8
+2
−4
−1
−0
+6%
2021
+13
−7
+12
+17%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Sep 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
Company is under investigation for potential securities law violations and breach of fiduciary duties in its $32.05 per share sale to CD&R and McKesson Corporation, suggesting possible unfair terms for shareholders.
Stock surged 32.9% on acquisition announcement at $32.05 per share, representing a 37% premium to previous closing price. However, long-term investors remain underwater as stock is still 15% below its 2026 high, indicating mixed historical performance.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.